Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

A Practical, One Clinic Visit, Population Pharmacokinetic (PK) Protocol for Generation of PK Profiles in Subjects with Severe Hemophilia a

Victor S. Blanchette, FRCP, Laura Tiseo, BSc, CCRP, David Lillicrap, MD, Shannon Jackson, MD FRCPC, Massimo Morfini, MD, Vanessa Bouskill, MN, Manuel Carcao, Margaret L. Rand, PhD, Derek Stephens, MSc, Liane Khoo, MD, Ester Zapotocka, MD, Vladimir Komrska, MD, Jan Blatny, MD PhD

Blood (2018) 132 (Supplement 1): 2480.

https://doi.org/10.1182/blood-2018-99-111024

Published: 2018

Journal Articles

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Blood (2018) 132 (Supplement 1): 2465.

https://doi.org/10.1182/blood-2018-99-113996

Published: 2018

Journal Articles

Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.

Luciano Baronciani, PhD, Flora Peyvandi, MD PhD, Anne Goodeve, PhD, Reinhard Schneppenheim, MDPhD, Zahra Badiee, Mohammad-Reza Baghaipour, Javier Battle, Erik Berntorp, MD PhD, Imre Bodó, MD PhD, Ulrich Budde, MD, Andrea Cairo, PhD, Giancarlo Castaman, Laura Crookes, Jeroen C.J. Eikenboom, MD, Peyman Eshghi, MD, Cosimo Ettorre, MD, Jenny Goudemand, MD PhD, Wolf Hassenpflug, Charles Richard Morris Hay, MDFRCP,FRCPath, Hamid Hoorfar, MD, Mehran Karimi, MD, Bijan Keikhaei, Riitta Lassila, MD PR, Frank W.G. Leebeek, MD PhD, Maria Fernanda Lopez Fernandez, Pier Mannuccio Mannucci, MD, Maria Gabriella Mazzucconi, MD, Massimo Morfini, MD, Nikolas Nikšić, Johannes Oldenburg, Florian Oyen, Rafael Parra Lòpez, Ian Peake, PhD, Gholamreza Toogeh, Alberto Tosetto, Marc Trossaert, Sayed Omid Reza Zekavat, MD, Eva M.K. Zetterberg, MD PhD, Augusto B Federici, MD

Blood (2018) 132 (Supplement 1): 1184.

https://doi.org/10.1182/blood-2018-99-114702

Published: 2018

Journal Articles

Comparative Assessment of the Performance of Pharmacokinetic Tools for Prophylactic Dosing of Antihemophilic Factor Recombinant Plasma/Albumin-Free Method (rAHF-PFM) Concentrate in Patients with Hemophilia A

Phillip Staibano, BSc, MSc, Alanna McEneny-King, MSc, PhDc), Massimo Morfini, MD, Gary Foster, PhD, Nicholas Hobson, Tamara Navarro-Ruan, MSc, Andrea N Edginton, PhD, Alfonso Iorio, MD PhD

Blood (2017) 130 (Supplement 1): 4934.

https://doi.org/10.1182/blood.V130.Suppl_1.4934.4934

Published: 2017

Journal Articles

Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates

Menchen Xi, Tamara Navarro-Ruan, MLIS. MD, Sunil Mammen, Victor S. Blanchette, MD FRCPC, Cedric R. Hermans, MD PhD, Massimo Morfini, MD, Peter W. Collins, MD, Kathelijn Fischer, MD PhD MSC, Ellis J. Neufeld, Guy Young, MD, Kaan Kavakli, MD, Paolo Radossi, MD, Amy Dunn, Lehana Thabane, PhD, Alfonso Iorio, MD PhD

Blood (2014) 124 (21): 2818.

https://doi.org/10.1182/blood.V124.21.2818.2818

Published: 2014

Journal Articles

The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease

Augusto B. Federici, Paolo Bucciarelli, Giancarlo Castaman, Maria G. Mazzucconi, Massimo Morfini, Angiola Rocino, Mario Schiavoni, Flora Peyvandi, Francesco Rodeghiero, Pier Mannuccio Mannucci

Blood (2014) 123 (26): 4037–4044.

https://doi.org/10.1182/blood-2014-02-557264

Published: 2014

Journal Articles

Factor VIII gene ( F8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

Corien L. Eckhardt, Alice S. van Velzen, Marjolein Peters, Jan Astermark, Paul P. Brons, Giancarlo Castaman, Marjon H. Cnossen, Natasja Dors, Carmen Escuriola-Ettingshausen, Karly Hamulyak, Daniel P. Hart, Charles R. M. Hay, Saturnino Haya, Waander L. van Heerde, Cedric Hermans, Margareta Holmström, Victor Jimenez-Yuste, Russell D. Keenan, Robert Klamroth, Britta A. P. Laros-van Gorkom, Frank W. G. Leebeek, Ri Liesner, Anne Mäkipernaa, Christoph Male, Evelien Mauser-Bunschoten, Maria G. Mazzucconi, Simon McRae, Karina Meijer, Michael Mitchell, Massimo Morfini, Marten Nijziel, Johannes Oldenburg, Kathelijne Peerlinck, Pia Petrini, Helena Platokouki, Sylvia E. Reitter-Pfoertner, Elena Santagostino, Piercarla Schinco, Frans J. Smiers, Berthold Siegmund, Annarita Tagliaferri, Thynn T. Yee, Pieter Willem Kamphuisen, Johanna G. van der Bom, Karin Fijnvandraat

Blood (2013) 122 (11): 1954–1962.

https://doi.org/10.1182/blood-2013-02-483263

Published: 2013

Includes: Supplemental data

Journal Articles

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients

Elena Santagostino, Claude Negrier, Robert Klamroth, Andreas Tiede, Ingrid Pabinger-Fasching, Christine Voigt, Iris Jacobs, Massimo Morfini

Blood (2012) 120 (12): 2405–2411.

https://doi.org/10.1182/blood-2012-05-429688

Published: 2012

Journal Articles

Pharmacokinetics of Factor VII

Massimo Morfini, Uriel Martinowitz, Angelika Batorova, MD, PhD, Alberto Dolce, PhD, Mariasanta Napolitano, MD, Jorgen Ingerslev, Jean-Francois Schved, Guglielmo Mariani, MD

Blood (2011) 118 (21): 2259.

https://doi.org/10.1182/blood.V118.21.2259.2259

Published: 2011

Journal Articles

Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis

Uri Martinowitz, MD, Amy D. Shapiro, MD, Doris V. Quon, MD, PhD, Miguel Antonio Escobar, MD, Christine L Kempton, MD, MSc, Peter Collins, MD, Pratima Chowdary, MD, Michael Makris, MD, Pier Mannuccio Mannucci, MD, Massimo Morfini, MD, Leonard A. Valentino, MD, Edward D. Gomperts, MD, Martin Lee, PhD

Blood (2011) 118 (21): 2267.

https://doi.org/10.1182/blood.V118.21.2267.2267

Published: 2011

Journal Articles

Safety and Preliminary Efficacy of Recombinant Activated FVII Analog (NN1731) In the Treatment of Joint Bleeds In Congenital Hemophilia Patients with Inhibitors

Erich de Paula, Kaan Kavakli, Johnny Mahlangu, Yasmin Ayob, Steven R. Lentz, Massimo Morfini, László Nemes, Silva Zupancic Salek, Midori Shima, Jerzy Windyga, Silke Ehrenforth, Henning Friis Andersen, Ampaiwan Chuansumrit, and on behalf of 1804 (ADEPT-1) Investigators

Blood (2010) 116 (21): 719.

https://doi.org/10.1182/blood.V116.21.719.719

Published: 2010

Journal Articles

Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients.

Augusto B. Federici, Paolo Bucciarelli, MD, Alfonso Iorio, Giancarlo Castaman, Maria Gabriella Mazzucconi, Massimo Morfini, Angiola Rocino, MD, Pier M. Mannucci, MD

Blood (2009) 114 (22): 3494.

https://doi.org/10.1182/blood.V114.22.3494.3494

Published: 2009

Journal Articles

Patients with Hemophilia Have Increased Numbers and Pericyte Coverage of Synovial Vessels.

Eva Zetterberg, Massimo Morfini, Richard Wallensten, Jan Palmblad, Holmström Margareta

Blood (2009) 114 (22): 3053.

https://doi.org/10.1182/blood.V114.22.3053.3053

Published: 2009

Journal Articles

Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders

Giuseppe Tagariello, Alfonso Iorio, Elena Santagostino, Massimo Morfini, Ruggero Bisson, Massimo Innocenti, Maria Elisa Mancuso, Maria Gabriella Mazzucconi, Gian Luigi Pasta, Paolo Radossi, Giuseppina Rodorigo, Cristina Santoro, Roberto Sartori, Antonio Scaraggi, Luigi Pier Solimeno, Pier Mannuccio Mannucci

Blood (2009) 114 (4): 779–784.

https://doi.org/10.1182/blood-2009-01-195313

Published: 2009

Journal Articles

Efficacy and Safety of Secondary Prophylactic Versus On-Demand Sucrose-Formulated Recombinant Factor VIII Treatment in Adults with Severe Hemophilia A: Results from a 13-Month Crossover Study

Peter Collins, Albert Faradji, Massimo Morfini, Monika Maas Enriquez, MD, Eduard Gorina, MD, Lawrence Schwartz, Georg Lemm, MD, PhD

Blood (2008) 112 (11): 516.

https://doi.org/10.1182/blood.V112.11.516.516

Published: 2008

Journal Articles

Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients.

Augusto B. Federici, MD, Paolo Bucciarelli, MD, Giancarlo Castaman, MD, Maria G. Mazzucconi, MD, Massimo Morfini, MD, Angiola Rocino, MD, Mario Schiavoni, MD, Francesco Rodeghiero, MD, Pier M. Mannucci, MD

Blood (2007) 110 (11): 713.

https://doi.org/10.1182/blood.V110.11.713.713

Published: 2007

Journal Articles

Preliminary Observations from the European Study on Orthopedic Status (ESOS) in Hemophilia Patients with Inhibitors.

Massimo Morfini, Saturnino Haya, Hartmut Pollmann, Berthold Siegmund, Natalie Stieltjes, Gerry Dolan, Christopher Ludlam

Blood (2006) 108 (11): 1037.

https://doi.org/10.1182/blood.V108.11.1037.1037

Published: 2006

Journal Articles

A Randomized Crossover Study of High- and Standard-Dose Recombinant Factor VIIa for Treatment of Hemarthroses in Hemophiliacs with Inhibitors.

Elena Santagostino, MD, PhD, Maria E. Mancuso, MD, Angiola Rocino, MD, Giacomo Mancuso, MD, Francesco A. Scaraggi, MD, Massimo Morfini, MD, Filomena Daniele, MD, Giovanni Barillari, MD, Pier M. Mannucci, MD

Blood (2005) 106 (11): 323.

https://doi.org/10.1182/blood.V106.11.323.323

Published: 2005

Journal Articles

TT virus contaminates first-generation recombinant factor VIII concentrates

Alberta Azzi, Riccardo De Santis, Massimo Morfini, Krystyna Zakrzewska, Roberto Musso, Elena Santagostino, Giancarlo Castaman

Blood (2001) 98 (8): 2571–2573.

https://doi.org/10.1182/blood.V98.8.2571

Published: 2001

NARROW

A Practical, One Clinic Visit, Population Pharmacokinetic (PK) Protocol for Generation of PK Profiles in Subjects with Severe Hemophilia a

Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project)

Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease.

Comparative Assessment of the Performance of Pharmacokinetic Tools for Prophylactic Dosing of Antihemophilic Factor Recombinant Plasma/Albumin-Free Method (rAHF-PFM) Concentrate in Patients with Hemophilia A

Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates

The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease

Factor VIII gene ( F8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients

Pharmacokinetics of Factor VII

Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis

Safety and Preliminary Efficacy of Recombinant Activated FVII Analog (NN1731) In the Treatment of Joint Bleeds In Congenital Hemophilia Patients with Inhibitors

Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients.

Patients with Hemophilia Have Increased Numbers and Pericyte Coverage of Synovial Vessels.

Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders

Efficacy and Safety of Secondary Prophylactic Versus On-Demand Sucrose-Formulated Recombinant Factor VIII Treatment in Adults with Severe Hemophilia A: Results from a 13-Month Crossover Study

Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients.

Preliminary Observations from the European Study on Orthopedic Status (ESOS) in Hemophilia Patients with Inhibitors.

A Randomized Crossover Study of High- and Standard-Dose Recombinant Factor VIIa for Treatment of Hemarthroses in Hemophiliacs with Inhibitors.

TT virus contaminates first-generation recombinant factor VIII concentrates

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only